Bortezomib, a first-in-class proteasome inhibitor, has emerged as a beacon of hope in the fight against cancer. Its targeted action against specific cellular processes disrupts cancer cell growth and proliferation, making it a potent weapon against multiple myeloma, mantle cell lymphoma, and other malignancies. This innovative approach has propelled Bortezomib to the forefront of the global oncology market, attracting a diverse range of buyers seeking its life-saving potential. Top Global Buyers of Bortezomib: Pharmaceutical companies: Giants like Janssen Pharmaceuticals and Takeda utilize Bortezomib under their brand names (Velcade® and Kyprolis®) for various cancer indications. Hospitals and cancer centers: These institutions directly administer Bortezomib to patients, making them crucial buyers at…